文献速递系统性红斑狼疮

基于实际体重的高剂量羟氯喹与SLE flare风险降低相关且耐受性维持

Higher hydroxychloroquine dose based on actual body weight is associated with lower SLE flare risks while maintaining tolerability.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究纳入182例SLE患者,按实际体重(ABW)分为羟氯喹≥5 mg/kg(高剂量组)与<5 mg/kg(低剂量组),采用逆概率治疗加权调整背景。高剂量组与低剂量组5年因不良事件停药率无显著差异,但高剂量组3年无flare率数值更高,且每增加0.2 mg/kg羟氯喹剂量flare风险降低(HR 0.91,95%CI 0.84-0.99)。

要点

  • 基于ABW的羟氯喹高剂量(≥5 mg/kg)与低剂量组因不良事件停药率无显著差异。
  • 高剂量组3年无flare率数值上高于低剂量组,但差异未达统计学显著。
  • 每增加0.2 mg/kg羟氯喹剂量,flare风险降低(HR 0.91,95%CI 0.84-0.99)。

核心结论

  • 高剂量与低剂量羟氯喹在疗效和安全性上未观察到明确差异,但较高羟氯喹剂量与flare风险降低相关。
  • 较低羟氯喹剂量可能与SLE患者flare风险升高相关,提示基于实际体重给药的重要性。

研究设计与样本

  • 回顾性队列研究,纳入182例SLE患者,按实际体重(ABW)分为羟氯喹≥5 mg/kg(高剂量组)与<5 mg/kg(低剂量组)。
  • 采用逆概率治疗加权(IPTW)方法调整患者背景,评估总体队列(组1)因不良事件停药率。
  • 在病程≥1年(组2)及羟氯喹起始后未加用其他免疫抑制剂和生物制剂(组3)的亚组中比较flare率、泼尼松剂量和血清学数据。

主要发现

  • 组2中高剂量组与低剂量组3年无flare率分别为75.0%和60.7%(P=0.239)。
  • 组3中高剂量组与低剂量组3年无flare率分别为79.2%和57.8%(P=0.141)。
  • 组3中羟氯喹剂量每增加0.2 mg/kg,flare风险降低(HR 0.91;95%CI 0.84-0.99)。

关键数值与推荐

  • 高剂量定义为羟氯喹剂量≥5 mg/kg实际体重,低剂量定义为<5 mg/kg实际体重。
  • 组3中羟氯喹剂量每增加0.2 mg/kg,flare风险的HR为0.91(95%CI 0.84-0.99)。

临床怎么用

  • 对于SLE患者,可考虑基于实际体重计算羟氯喹剂量,较高剂量(≥5 mg/kg)可能有助于降低flare风险且耐受性可接受。
  • 在决定羟氯喹剂量时,应结合患者实际体重评估flare风险与不良事件风险。

局限性

  • 高剂量组与低剂量组在flare率比较中差异未达统计学显著(P=0.239和P=0.141),结果需谨慎解读。
  • 本研究为单中心回顾性研究,样本量有限(182例),结论需更大规模前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The effects of HCQ dose based on actual body weight (ABW) on SLE remain unclear. We investigated the effects of HCQ dose based on ABW of patients with SLE. METHODS: Patients were classified into ≥5 mg/kg ABW [high dose (HD)] and <5 mg/kg ABW [low dose (LD)] groups. Patient backgrounds were adjusted using inverse probability of treatment weighting method. The discontinuation rate owing to adverse events of overall cohort (group 1) was evaluated. Subgroups with a disease duration ≥1 year (group 2) and without additional immunosuppressive agents and biologics after HCQ initiation (group 3) were compared with evaluated flare rates, prednisolone dose and serological data. RESULTS: Among 182 patients in group 1, 60 (33%) comprised the HD group. Five-year discontinuation rates were 18.9% and 13.6% in the HD and LD groups, respectively (P = 0.314). Three-year flare-free rates in HD group were higher than those in LD group: 75.0% (HD) vs 60.7% (LD) (P = 0.239) in group 2, and 79.2% (HD) vs 57.8% (LD) (P = 0.141) in group 3. In group 3, each 0.2 mg/kg increase in the HCQ dose reduced flares (hazard ratio 0.91; 95% CI 0.84-0.99). CONCLUSION: No clear differences in efficacy and safety were observed between the HD and LD groups; however, a higher HCQ dose was associated with a reduced flare risk. Our findings suggest that a lower HCQ dose may be associated with a higher flare risk in patients with SLE, highlighting the importance of HCQ dose based on ABW.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yamamoto S, Sato T, Nagatani K, et al. Higher hydroxychloroquine dose based on actual body weight is associated with lower SLE flare risks while maintaining tolerability. Rheumatology (Oxford). 2026. PMID: 42104096. doi:10.1093/rheumatology/keag242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。